M.D. Anderson Cancer Center: Lymphoma, Large-Cell, Anaplastic trials
The registry lists 11 Lymphoma, Large-Cell, Anaplastic studies with M.D. Anderson Cancer Center as lead sponsor. 0 are open to participants now and 6 have results posted.
Phase 1 7Phase 2 6No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin LymphomasCompletedNCT04074746Phase 1/2Results posted
- Study of Pembrolizumab (MK-3475) in Combination With RomidepsinCompletedNCT03278782Phase 1/2Results posted
- Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)TerminatedNCT02169505Phase 2Results posted
- Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's LymphomaTerminatedNCT00810576Phase 2Results posted
- SAHA + CHOP in Untreated T-cell Non-Hodgkin's LymphomaCompletedNCT00787527Phase 1/2Results posted
- Methadone, Morphine, or Oxycodone in Treating Pain in Patients With CancerTerminatedNCT00726830Not applicableResults posted
- Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell LymphomasWithdrawnNCT03205891Phase 1
- Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell LymphomaCompletedNCT01590732Phase 1
- Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With MalignanciesWithdrawnNCT01101412Phase 1/2
- Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related InfectionWithdrawnNCT00378781Not applicable
- Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedNCT00005092Phase 1